PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PathXL

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PathXL a Winner in Deloitte Technology Fast 50 - PathXL attributes its growth to its ground breaking software that has the potential to revolutionise cancer analysis and diagnosis - PathXL.com / Deloitte.com
PathXL a Winner in Deloitte Technology Fast 50

 

NewswireToday - /newswire/ - Belfast, Ireland, 2012/11/21 - PathXL attributes its growth to its ground breaking software that has the potential to revolutionise cancer analysis and diagnosis - PathXL.com / Deloitte.com. NYSE: PHG, AEX: PHIA

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

PathXL today announced that it ranked number 13 in the 2012 Deloitte Technology Fast 50, a ranking of the 50 fastest growing technology companies in Ireland. On a local level, PathXL were ranked third in the Northern Irish market. Rankings are based on average percentage revenue growth over five years.

PathXL’s CEO, Des Speed, commented,
“We are delighted to receive industry recognition for achieving sustained success over the last five years. PathXL is committed to delivering innovative, effective and reliable software to pathologists, scientists and students in Research, Biobanking, Clinical and Education settings worldwide.”

The Fast 50 programme, now in its thirteenth year in Ireland, ranks the fastest-growing technology companies in the Republic of Ireland and Northern Ireland. This year, there are 15 companies from Northern Ireland in the ranking. The average growth rate of the Fast 50 companies named in this year’s ranking is 556%.

Announcing the winners of the Technology Fast 50 programme, David Crawford, Partner with Deloitte Belfast said:
“Each year, we are considerably enthused by the resilience and tenacity of the indigenous technology sector as they demonstrate high levels of growth amidst challenging economic times. One of the key drivers of this growth has been their ability to capitalise on international markets. Many companies from across Northern Ireland now have an increased focus on international expansion as a way to drive sustainable growth.

The indigenous technology sector has been a trailblazer in this regard – some of our most successful technology companies have long been internationalising their IP and reaping the rewards. It’s encouraging to observe that so many of our Fast 50 winning companies are seeking to exploit both local and global markets to their best advantage.”

The awards took place in the Guinness Storehouse on Friday 16 November. Dr Chris Horn, co-founder and former CEO Iona Technologies, was keynote speaker at the event.

Details of the Deloitte Technology Fast 50 ranking list are available to download at fast50.ie/.

About PathXL
PathXL (pathxl.com) specialises in web-based software and workflows for Digital Pathology. Its PathXL™ Manager product provides a robust, secure and open web-based platform to enable digital pathology users across all fields to manage, view and collaborate around virtual slides easily and efficiently. In addition, PathXL provides a range of applications and workflows on top of PathXL™ Manager to deliver specific solutions in Research, Biobanking, Clinical and Education settings.

PathXL also provides a full range of supporting services, including scanning, hosting, image analysis and consultancy. PathXL operates in the UK, Europe and North America. PathXL is a privately owned company, headquartered in Belfast, Northern Ireland.

About Deloitte
Deloitte (deloitte.com) refers to one or more of Deloitte Touche Tohmatsu Limited, a private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please visit the website for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.

The information contained in this press release is correct at the time of going to press.

Deloitte’s 1,200 people in Dublin, Cork and Limerick provide audit, tax, consulting, and corporate finance services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges.

Deloitte has in the region of 200,000 professionals, all committed to becoming the standard of excellence.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PathXL

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PathXL a Winner in Deloitte Technology Fast 50

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

PathXL | Deloitte
Publisher Contact: Press Office - PathXL.com 
+44(0)28 9073 8712 sales[.]pathxl.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PathXL securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PathXL / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)